A. Gils

P. Rutgeerts, S. Vermeire, A. Gils, 2017, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Post-Induction Adalimumab Concentration is Associated with Short-Term Mucosal Healing in Patients with Ulcerative Colitis

P. Rutgeerts, S. Vermeire, A. Gils, 2017, Journal of Crohn's & colitis.

Eczematous eruption after guselkumab treatment for psoriasis

A. Gils, T. Hillary, B. Reyn, 2019, JAAD case reports.

Prediction and Reduction of the Aggregation of Monoclonal Antibodies

F. Rousseau, A. Gils, P. Schulz, 2017, Journal of molecular biology.

Inhibition of plasmin-mediated TAFI activation may affect development but not progression of abdominal aortic aneurysms

N. Yuldasheva, A. Gils, M. Bailey, 2017, PloS one.

Optimising infliximab induction dosing for patients with ulcerative colitis

S. Vermeire, T. Bouillon, A. Gils, 2019, British journal of clinical pharmacology.

Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease.

K. Van Steen, S. Simoens, P. Rutgeerts, 2015, Gastroenterology.

A panel to predict long-term outcome of infliximab therapy for patients with ulcerative colitis.

P. Rutgeerts, S. Vermeire, A. Gils, 2015, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Evaluating Efficacy, Safety, and Pharmacokinetics After Switching From Infliximab Originator to Biosimilar CT-P13: Experience From a Large Tertiary Referral Center.

S. Vermeire, A. Gils, M. Ferrante, 2019, Inflammatory bowel diseases.

Efficacy, Pharmacokinetics, and Immunogenicity is Not Affected by Switching From Infliximab Originator to a Biosimilar in Pediatric Patients With Inflammatory Bowel Disease

S. Vermeire, A. Gils, M. Ferrante, 2019, Therapeutic drug monitoring.

Effect of vedolizumab dose intensification on serum drug concentrations and regain of response in inflammatory bowel disease patients with secondary loss of response

D. Franchimont, S. Vermeire, A. Gils, 2021, GastroHep.

Early vedolizumab trough levels at induction in inflammatory bowel disease patients with treatment failure during maintenance

D. Franchimont, L. Amininejad, J. Devière, 2019, European journal of gastroenterology & hepatology.

Antibody Response to Infliximab and its Impact on Pharmacokinetics can be Transient

P. Rutgeerts, S. Vermeire, A. Gils, 2013, The American Journal of Gastroenterology.

Switch to adalimumab in patients with Crohn's disease controlled by maintenance infliximab: prospective randomised SWITCH trial

P. Rutgeerts, S. Vermeire, A. Gils, 2011, Gut.

Higher Infliximab Trough Levels Are Associated With Better Outcome in Paediatric Patients With Inflammatory Bowel Disease

S. Vermeire, A. Gils, M. Ferrante, 2018, Journal of Crohn's & colitis.

Influence of early adalimumab serum levels on immunogenicity and long‐term outcome of anti‐TNF naive Crohn's disease patients: the usefulness of rapid testing

S. Vermeire, T. Van Stappen, A. Gils, 2018, Alimentary pharmacology & therapeutics.

Mo1841 - Infliximab Exposure Predicts Superior Endoscopic Outcomes in Patients with Active Crohn's Disease: Pharmacokineticpharmacodynamic Analysis of Tailorix

S. Vermeire, A. Gils, G. D'Haens, 2018 .

DOP047 Infliximab exposure predicts superior endoscopic outcomes in patients with active Crohn’s disease: pharmacokinetic–pharmacodynamic analysis of TAILORIX

S. Vermeire, A. Gils, G. D'Haens, 2018 .

Clinical relevance of detecting anti-infliximab antibodies with a drug-tolerant assay: post hoc analysis of the TAXIT trial

S. Vermeire, T. Van Stappen, A. Gils, 2017, Gut.

Therapeutic Drug Monitoring During Induction of Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease: Defining a Therapeutic Drug Window.

A. Gils, M. Ferrante, A. Cheifetz, 2017, Inflammatory bowel diseases.

Variability in Golimumab Exposure: A 'Real-Life' Observational Study in Active Ulcerative Colitis.

S. Vermeire, T. Van Stappen, A. Gils, 2016, Journal of Crohn's & colitis.

Harmonization of Infliximab and Anti-Infliximab Assays Facilitates the Comparison Between Originators and Biosimilars in Clinical Samples

S. Vermeire, T. Van Stappen, A. Gils, 2016, Inflammatory bowel diseases.

Infliximab Concentration Thresholds During Induction Therapy Are Associated With Short-term Mucosal Healing in Patients With Ulcerative Colitis.

P. Rutgeerts, S. Vermeire, T. Van Stappen, 2016, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Long-term outcome of patients with Crohn's disease who discontinued infliximab therapy upon clinical remission.

P. Rutgeerts, S. Vermeire, A. Gils, 2015, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Antibodies to adalimumab are associated with future inflammation in Crohn's patients receiving maintenance adalimumab therapy: a post hoc analysis of the Karmiris trial

S. Vermeire, A. Gils, M. Ferrante, 2015, Gut.

Withdrawal of immunomodulators after co-treatment does not reduce trough level of infliximab in patients with Crohn's disease.

K. Van Steen, P. Rutgeerts, S. Vermeire, 2015, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Prior response to infliximab and early serum drug concentrations predict effects of adalimumab in ulcerative colitis

P. Rutgeerts, S. Vermeire, A. Gils, 2014, Alimentary pharmacology & therapeutics.

Early trough levels and antibodies to infliximab predict safety and success of reinitiation of infliximab therapy.

P. Rutgeerts, S. Vermeire, A. Gils, 2014, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Dose de‐escalation to adalimumab 40 mg every 3 weeks in patients with Crohn's disease – a nested case–control study

S. Vermeire, A. Gils, M. Ferrante, 2017, Alimentary pharmacology & therapeutics.

Sa1956 Post-Induction Adalimumab Concentration Threshold Is Associated With Short-Term Mucosal Healing in Patients With Ulcerative Colitis

P. Rutgeerts, S. Vermeire, A. Gils, 2016 .

Therapeutic Drug Monitoring During Induction of Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease: Defining a Therapeutic Drug Window.

A. Gils, M. Ferrante, A. Cheifetz, 2017, Inflammatory bowel diseases.

Infliximab Concentrations During Induction Are Predictive for Endoscopic Remission in Pediatric Patients With Inflammatory Bowel Disease Under Combination Therapy.

S. Vermeire, A. Gils, M. Ferrante, 2021, The Journal of pediatrics.

Combining Therapeutic Drug Monitoring with Biosimilars, a Strategy to Improve the Efficacy of Biologicals for Treating Inflammatory Bowel Diseases at an Affordable Cost

A. Gils, 2017, Digestive Diseases.

Adequate Infliximab Exposure During Induction Predicts Remission in Paediatric Patients With Inflammatory Bowel Disease

S. Vermeire, A. Gils, M. Ferrante, 2019, Journal of pediatric gastroenterology and nutrition.

Infliximab Trough Levels at Induction to Predict Treatment Failure During Maintenance

D. Franchimont, J. Toubeau, L. Amininejad, 2017, Inflammatory bowel diseases.

The relationship between in fl iximab concentrations , antibodies to in fl iximab and disease activity in Crohn ’ s disease

G. Greenberg, P. Rutgeerts, S. Vermeire, 2014 .

The association between etanercept serum concentration and psoriasis severity is highly age-dependent.

K. Van Steen, A. Gils, S. Segaert, 2017, Clinical science.

PAI-1 mediates the antiangiogenic and profibrinolytic effects of 16K prolactin

P. Carmeliet, J. Martial, A. Gils, 2014, Nature Medicine.

Dose-dependent modulation of choroidal neovascularization by plasminogen activator inhibitor type I: implications for clinical trials.

J. Rakic, V. Lambert, P. Carmeliet, 2003, Investigative ophthalmology & visual science.

Plant pectin methylesterase and its inhibitor from kiwi fruit: Interaction analysis by surface plasmon resonance

Ruben P. Jolie, M. Hendrickx, A. Loey, 2010 .

Comparison of immunoassays for measuring serum levels of golimumab and antibodies against golimumab in ulcerative colitis: a retrospective observational study.

A. Gils, J. Marini, X. Roblin, 2019, Therapeutic drug monitoring.

Development and validation of immunoassays for monitoring of guselkumab and anti-guselkumab antibodies in patients with moderate-to-severe psoriasis.

A. Gils, G. Compernolle, E. Brouwers, 2020, Journal of pharmaceutical and biomedical analysis.

Generation and characterization of a unique panel of anti-adalimumab specific antibodies and their application in therapeutic drug monitoring assays.

S. Vermeire, J. Lammertyn, A. Gils, 2016, Journal of pharmaceutical and biomedical analysis.

Development of sandwich‐type ELISAs for the quantification of rat and murine thrombin activatable fibrinolysis inhibitor in plasma

A. Gils, P. Declerck, J. Meijers, 2007, Journal of thrombosis and haemostasis : JTH.

Anti-infliximab antibodies: How to compare old and new data?

T. Van Stappen, A. Gils, S. Tops, 2020, Journal of pharmaceutical and biomedical analysis.

Immunogenicity is not the driving force of treatment failure in vedolizumab‐treated inflammatory bowel disease patients

S. Vermeire, A. Gils, M. Ferrante, 2019, Journal of gastroenterology and hepatology.

Antibodies Toward Vedolizumab Appear from the First Infusion Onward and Disappear Over Time

S. Vermeire, A. Gils, M. Ferrante, 2017, Inflammatory bowel diseases.

Current Practice for Therapeutic Drug Monitoring of Biopharmaceuticals in Inflammatory Bowel Disease

T. Van Stappen, A. Gils, I. Detrez, 2017, Therapeutic drug monitoring.

Accounting for Pharmacokinetic Variability of Certolizumab Pegol in Patients with Crohn’s Disease

D. Mould, A. Gils, W. Sandborn, 2017, Clinical Pharmacokinetics.

Validation of a sample pretreatment protocol to convert a drug-sensitive into a drug-tolerant anti-infliximab antibody immunoassay.

S. Vermeire, T. Van Stappen, A. Gils, 2017, Drug testing and analysis.

An Optimized Anti-infliximab Bridging Enzyme-linked Immunosorbent Assay for Harmonization of Anti-infliximab Antibody Titers in Patients with Inflammatory Bowel Diseases

S. Vermeire, T. Van Stappen, A. Gils, 2015, Inflammatory bowel diseases.

Predicting iron absorption from an effervescent iron supplement in obese patients before and after Roux-en-Y gastric bypass: a preliminary study.

A. Gils, C. Matthys, B. Van der Schueren, 2019, Journal of trace elements in medicine and biology : organ of the Society for Minerals and Trace Elements.

Fibrinogen Contains Cryptic PAI-1 Binding Sites That Are Exposed on Binding to Solid Surfaces or Limited Proteolysis

A. Gils, C. Cierniewski, J. Szymański, 2005, Arteriosclerosis, thrombosis, and vascular biology.

Achieving Mucosal Healing in Inflammatory Bowel Diseases: Which Drug Concentrations Need to Be Targeted?

A. Gils, Debby Thomas, N. Van den Berghe, 2019, Clinical pharmacology and therapeutics.

Long term evolution and impact of immunomodulator cotreatment and withdrawal on infliximab on trough levels in 223 patients with Crohn's disease

P. Rutgeerts, S. Vermeire, I. Cleynen, 2011 .

Species-dependent molecular drug targets in plasminogen activator inhibitor-1 (PAI-1)

A. Gils, P. Declerck, G. Compernolle, 2009, Thrombosis and Haemostasis.

Quantitation of Vervet Monkey (Chlorocebus aethiops) plasminogen activator inhibitor-1 in plasma and platelets

A. Gils, P. Declerck, K. Verbeke, 2006, Thrombosis and Haemostasis.

The story of the serpin plasminogen activator inhibitor 1: is there any need for another mutant?

A. Gils, P. Declerck, B. D. De Taeye, 2004, Thrombosis and Haemostasis.

Biochemical importance of glycosylation of plasminogen activator inhibitor-1

J. Enghild, A. Gils, P. Declerck, 2003, Thrombosis and Haemostasis.

Glycosylation influences the stability of human plasminogen activator inhibitor-1.

A. Gils, P. Declerck, Britt Van De Craen, 2012, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

Elucidation of the epitope of a latency-inducing antibody: identification of a new molecular target for PAI-1 inhibition

A. Gils, P. Declerck, G. Compernolle, 2017 .

Conformational (in)stability of rat vs. human activated thrombin activatable fibrinolysis inhibitor

A. Gils, P. Declerck, R. Vancraenenbroeck, 2008, Journal of thrombosis and haemostasis : JTH.

Characterization of rat thrombin‐activatable fibrinolysis inhibitor (TAFI) – a comparative study assessing the biological equivalence of rat, murine and human TAFI

A. Gils, A. Macovei, G. Compernolle, 2006, Journal of thrombosis and haemostasis : JTH.

Migration of the activation peptide of thrombin‐activatable fibrinolysis inhibitor (TAFI) during SDS–polyacrylamide gel electrophoresis

A. Gils, P. Declerck, D. Rijken, 2004, Journal of thrombosis and haemostasis : JTH.

Development of an immunological toolbox to detect endogenous and exogenous pectin methylesterase in plant-based food products

M. Hendrickx, A. Loey, A. Gils, 2011 .

Thrombin activatable fibrinolysis inhibitor is associated with severity and outcome of severe meningococcal infection in children

A. Gils, J. Hazelzet, P. Declerck, 2008, Journal of thrombosis and haemostasis : JTH.

The pro‐ or antiangiogenic effect of plasminogen activator inhibitor 1 is dose dependent

L. Devy, P. Carmeliet, J. Foidart, 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

Letter: overcoming secondary loss of response to infliximab—it is not the drug, it is how you use it! Authors’ reply

A. Gils, E. Dreesen, 2018, Alimentary pharmacology & therapeutics.

Advances in understanding pectin methylesterase inhibitor in kiwi fruit: an immunological approach

Ruben P. Jolie, M. Hendrickx, A. Gils, 2011, Planta.

Micronutrient intake, from diet and supplements, and association with status markers in pre- and post-RYGB patients.

A. Gils, C. Matthys, B. Van der Schueren, 2017, Clinical nutrition.

Improved functionalization of oleic acid-coated iron oxide nanoparticles for biomedical applications

Maarten Bloemen, Ward Brullot, Thierry Verbiest, 2012, Journal of Nanoparticle Research.

Golimumab Dried Blood Spot Analysis (GOUDA): a Prospective Trial Showing Excellent Correlation with Venepuncture Samples and More Detailed Pharmacokinetic Information

S. Vermeire, A. Gils, M. Ferrante, 2018, The AAPS Journal.

Generation and characterization of inhibitory nanobodies towards thrombin activatable fibrinolysis inhibitor

S. Muyldermans, A. Gils, G. Hassanzadeh-Ghassabeh, 2010, Journal of thrombosis and haemostasis : JTH.

Pharmacodynamic Monitoring of Biological Therapies in Chronic Inflammatory Diseases.

A. Gils, E. Dreesen, 2019, Therapeutic drug monitoring.

Pharmacodynamic monitoring of biological therapies in chronic inflammatory diseases.

A. Gils, E. Dreesen, 2019, Therapeutic drug monitoring.

A Prospective Trial with Long Term Follow-up of Patients With Severe, Steroid-Resistant Ulcerative Colitis Who Received Induction Therapy With Cyclosporine and Were Maintained With Vedolizumab.

A. Gils, B. Subotić, D. Tarabar, 2022, Inflammatory bowel diseases.

UEG Week 2016 Oral Presentations

A. Gils, M. Ferrante, M. Noman, 2016 .

The structural basis for the pathophysiological relevance of PAI-1 in cardiovascular diseases and the development of potential PAI-1 inhibitors

A. Gils, P. Declerck, 2004, Thrombosis and Haemostasis.

Subcutaneous Absorption Contributes to Observed Interindividual Variability in Adalimumab Serum Concentrations in Crohn's Disease: A Prospective Multicentre Study.

S. Vermeire, A. Gils, M. Ferrante, 2019, Journal of Crohn's & colitis.

Early vedolizumab trough levels predict combined endoscopic and clinical remission in inflammatory bowel disease

A. Gils, G. Novak, J. Hanžel, 2019, United European gastroenterology journal.

Evidence to Support Monitoring of Vedolizumab Trough Concentrations in Patients With Inflammatory Bowel Diseases

S. Vermeire, A. Gils, M. Ferrante, 2018, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Detection of infliximab levels and anti‐infliximab antibodies: a comparison of three different assays

S. Vermeire, A. Gils, J. Kleibeuker, 2012, Alimentary pharmacology & therapeutics.

Molecular mechanism of SSR128129E, an extracellularly acting, small-molecule, allosteric inhibitor of FGF receptor signaling.

T. Blundell, P. Carmeliet, K. Saxena, 2013, Cancer cell.

The Biochemistry, Physiology and Pathological roles of PAI-1 and the requirements for PAI-1 inhibition in vivo.

A. Gils, P. Declerck, Britt Van De Craen, 2012, Thrombosis research.

Evidence for a Pre-latent Form of the Serpin Plasminogen Activator Inhibitor-1 with a Detached β-Strand 1C*

A. Gils, P. Declerck, P. Andreasen, 2006, Journal of Biological Chemistry.

Bioassay Development for Ultrasensitive Detection of Influenza A Nucleoprotein Using Digital ELISA.

J. Lammertyn, L. Stuyver, D. Spasic, 2016, Analytical chemistry.

A Genetic Variation in the Neonatal Fc-Receptor Affects Anti-TNF Drug Concentrations in Inflammatory Bowel Disease

S. Vermeire, I. Cleynen, A. Gils, 2016, The American Journal of Gastroenterology.

The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn's disease

G. Greenberg, P. Rutgeerts, S. Vermeire, 2014, Gut.

His374 of wheat endoxylanase inhibitor TAXI‐I stabilizes complex formation with glycoside hydrolase family 11 endoxylanases

Kurt Gebruers, Kristof Brijs, Guido Volckaert, 2005, The FEBS journal.

Monitoring a Combination of Calprotectin and Infliximab Identifies Patients With Mucosal Healing of Crohn's Disease.

S. Vermeire, E. Louis, A. Gils, 2020, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Pharmacokinetics and Exposure-response Relationship of Golimumab in Patients with Moderately-to-severely Active Ulcerative Colitis: Results from Phase 2/3 PURSUIT Induction and Maintenance Studies.

A. Gils, I. Detrez, 2017, Journal of Crohn's & colitis.

Rapid Test for Infliximab Drug Concentration Allows Immediate Dose Adaptation

S. Vermeire, T. Van Stappen, A. Gils, 2016, Clinical and translational gastroenterology.

692 Drug-Level Based Dosing Versus Symptom-Based Dose Adaptation in Patients With Crohn's Disease: A Prospective, Randomized Multicenter Study (TAILORIX)

D. Franchimont, M. Vos, S. Vermeire, 2016 .

Comparisons of Serum Infliximab and Antibodies-to-Infliximab Tests Used in Inflammatory Bowel Disease Clinical Trials of Remicade®

G. Shankar, T. Van Stappen, A. Gils, 2016, The AAPS Journal.

Preemptive Dose Optimization Using Therapeutic Drug Monitoring for Biologic Therapy of Crohn’s Disease: Avoiding Failure While Lowering Costs?

A. Gils, N. Vande Casteele, 2015, Digestive Diseases and Sciences.

Next generation point-of-care test for therapeutic drug monitoring of adalimumab in patients diagnosed with autoimmune diseases.

S. Vermeire, J. Lammertyn, D. Spasic, 2022, Biosensors & bioelectronics.

Clinical response correlates with 4‐week postinjection ustekinumab concentrations in patients with moderate‐to‐severe psoriasis†

J. Lambert, A. Gils, S. Lanssens, 2019, The British journal of dermatology.

Practical recommendations for the use of therapeutic drug monitoring of biopharmaceuticals in inflammatory diseases

A. Gils, P. Bossuyt, D. Mulleman, 2017, Clinical pharmacology : advances and applications.

Drug-concentration versus symptom-driven dose adaptation of Infliximab in patients with active Crohn's disease: a prospective, randomised, multicentre trial (Tailorix)

D. Franchimont, M. Vos, S. Vermeire, 2016 .

Plasminogen activator inhibitor 1. Structure of the native serpin, comparison to its other conformers and implications for serpin inactivation.

A. Gils, H. Nar, P. Declerck, 2000, Journal of molecular biology.

Characteristics of Skin Lesions Associated With AntiTumor Necrosis Factor Therapy in Patients With Inflammatory Bowel Disease

P. Rutgeerts, I. Cleynen, J. J. van den Oord, 2015, Annals of Internal Medicine.

Neutralisation of Soluble Tumor Necrosis Factor

A. Gils, E. Dreesen, 2015 .

Thrombin Activatable Fibrinolysis Inhibitor Activation Peptide Shows Association With All Major Subtypes of Ischemic Stroke and With TAFI Gene Variation

C. Ladenvall, C. Blomstrand, A. Gils, 2007, Arteriosclerosis, thrombosis, and vascular biology.

Cloning and paratope analysis of an antibody fragment, a rational approach for the design of a PAI‐1 inhibitor

A. Gils, K. Verbeke, A Gils, 2004, Journal of thrombosis and haemostasis : JTH.

Inhibition of plasminogen activator inhibitor‐1: antibody fragments and their unique sequences as a tool for the development of profibrinolytic drugs

A. Gils, A. Gils, P. Declerck, 2004, Journal of thrombosis and haemostasis : JTH.

Elucidation of the paratope of scFv-8H9D4, a PAI-1 neutralizing antibody derivative

A. Gils, P. Declerck, J. Stassen, 2003, Thrombosis and Haemostasis.

Antibody-modified iron oxide nanoparticles for efficient magnetic isolation and flow cytometric determination of L. pneumophila

Maarten Bloemen, Carla Denis, Thierry Verbiest, 2015, Microchimica Acta.

Tissue exposure does not explain non-response in ulcerative colitis patients with adequate serum vedolizumab concentrations.

S. Vermeire, A. Gils, M. Ferrante, 2020, Journal of Crohn's & colitis.

Adaptive antibody diversification through N-linked glycosylation of the immunoglobulin variable region

M. van der Burg, R. Toes, A. Gils, 2018, Proceedings of the National Academy of Sciences.

Value of drug level testing and antibody assays in optimising biological therapy

Ann Gils, S. Vermeire, A. Gils, 2012, Frontline Gastroenterology.

Impact of first-line infliximab on the pharmacokinetics of second-line vedolizumab in inflammatory bowel diseases

D. Franchimont, S. Vermeire, A. Gils, 2019, United European gastroenterology journal.

Maximal PAI-1 inhibition in vivo requires neutralizing antibodies that recognize and inhibit glycosylated PAI-1.

A. Gils, P. Declerck, Christine Vranckx, 2012, Thrombosis research.

Characterization of a panel of monoclonal antibodies toward mouse PAI-1 that exert a significant profibrinolytic effect in vivo.

A. Gils, P. Declerck, I. Scroyen, 2011, Thrombosis research.

Bispecific targeting of thrombin activatable fibrinolysis inhibitor and plasminogen activator inhibitor‐1 by a heterodimer diabody

A. Gils, N. Booth, J. Develter, 2008, Journal of thrombosis and haemostasis : JTH.

Elucidation of the Binding Regions of PAI-1 Neutralizing Antibodies Using Chimeric Variants of Human and Rat PAI-1

A. Gils, P. Declerck, I. Knockaert, 2001, Thrombosis and Haemostasis.

Innovative thrombolytic strategy using a heterodimer diabody against TAFI and PAI-1 in mouse models of thrombosis and stroke.

A. Gils, D. Vivien, P. Declerck, 2015, Blood.

In vitro and in vivo characterisation of the profibrinolytic effect of an inhibitory anti-rat TAFI nanobody

S. Muyldermans, A. Gils, P. Declerck, 2014, Thrombosis and Haemostasis.

Evaluation of the profibrinolytic properties of a bispecific antibody‐based inhibitor against human and mouse thrombin‐activatable fibrinolysis inhibitor and plasminogen activator inhibitor‐1

A. Gils, T. Wyseure, P. Declerck, 2013, Journal of thrombosis and haemostasis : JTH.

TAFIa inhibiting nanobodies as profibrinolytic tools and discovery of a new TAFIa conformation

S. Muyldermans, A. Gils, G. Hassanzadeh-Ghassabeh, 2011, Journal of thrombosis and haemostasis : JTH.

Development of a Genotype 325–Specific proCPU/TAFI ELISA

Els Brouwers, Ann Gils, A. Gils, 2003, Arteriosclerosis, thrombosis, and vascular biology.

Substrate behavior of plasminogen activator inhibitor-1 is not associated with a lack of insertion of the reactive site loop.

A. Gils, P. Declerck, I. Knockaert, 1995, Biochemistry.

Reply: To PMID 24486408.

S. Vermeire, A. Gils, F. Baert, 2015, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Characterization and Application of a Unique Panel of Monoclonal Antibodies Generated against Etanercept

A. Gils, K. de Vlam, E. Brouwers, 2016, The Journal of Immunology.

This information is current as against Etanercept Panel of Monoclonal Antibodies Generated Characterization and Application of a Unique de Vlam and Ann Gils

A. Gils, E. Brouwers, M. Peeters, 2016 .

Development of a Universal Anti-Adalimumab Antibody Standard for Interlaboratory Harmonization

Els Brouwers, Nick Geukens, Ann Gils, 2014, Therapeutic drug monitoring.

Letter: dry blood spots for anti‐TNF treatment monitoring in IBD

P. Rutgeerts, S. Vermeire, A. Gils, 2013, Alimentary pharmacology & therapeutics.

OP11 Individualised infliximab treatment using therapeutic drug monitoring: A prospective controlled Trough level Adapted infliXImab Treatment (TAXIT) trial

Ann Gils, P. Rutgeerts, S. Vermeire, 2012 .

OP10 Importance of trough levels and antibodies on the long-term efficacy of infliximab therapy in ulcerative colitis

P. Rutgeerts, S. Vermeire, I. Cleynen, 2012 .

Infliximab for Severe IV Steroid-Refractory Ulcerative Colitis: Can Infliximab Trough Levels Guide Our Management?

P. Rutgeerts, S. Vermeire, A. Gils, 2011 .

405 High Infliximab Trough Levels are Associated With Mucosal Healing in Crohn's Disease

P. Rutgeerts, S. Vermeire, I. Cleynen, 2010 .

The effect of dose escalation on trough levels in patients who lost response to infliximab

P. Rutgeerts, S. Vermeire, A. Gils, 2010 .

Characterization of a Novel Intracellular Endopeptidase of the α/β Hydrolase Family from Streptomyces coelicolor A3(2)

W. Baumeister, A. Gils, G. Schoofs, 2003, Journal of bacteriology.

A Population Pharmacokinetic and Exposure-Response Model of Golimumab for Targeting Endoscopic Remission in Patients With Ulcerative Colitis.

S. Vermeire, T. Bouillon, A. Gils, 2019, Inflammatory bowel diseases.

Evolution of cytokines and inflammatory biomarkers during infliximab induction therapy and the impact of inflammatory burden on primary response in patients with Crohn’s disease

S. Vermeire, I. Cleynen, A. Gils, 2017, Scandinavian journal of gastroenterology.

Randomised Controlled Trial of Drug Level Versus Clinically Based Dosing of Infliximab Maintenance Therapy in IBD: Final Results of the TAXIT Study

S. Simoens, P. Rutgeerts, S. Vermeire, 2013 .

Evaluating Efficacy, Safety, and Pharmacokinetics After Switching From Infliximab Originator to Biosimilar CT-P13: Experience From a Large Tertiary Referral Center.

S. Vermeire, A. Gils, M. Ferrante, 2019, Inflammatory bowel diseases.

407 Anti-TNFα Induced Severe Arthralgia as a Manifestation of Autoimmunity?

P. Rutgeerts, S. Vermeire, A. Gils, 2010 .

Incidence of acute severe infusion reactions to infliximab depends on definition used rather than assay

S. Vermeire, A. Gils, G. Van Assche, 2011, Alimentary pharmacology & therapeutics.

Sa1247 Antibodies to Adalimumab Predict Inflammation in Crohn's Patients on Maintenance Adalimumab Therapy

S. Vermeire, A. Gils, F. Baert, 2014 .

Evaluating an easy sampling method using dried blood spots to determine vedolizumab concentrations.

S. Vermeire, A. Gils, M. Ferrante, 2020, Journal of pharmaceutical and biomedical analysis.

Editorial: variability in adalimumab trough and peak serum concentrations

A. Gils, N. Vande Casteele, 2017, Alimentary pharmacology & therapeutics.

The effect of aging on infliximab exposure and response in patients with inflammatory bowel diseases

S. Vermeire, A. Gils, M. Ferrante, 2021, British journal of clinical pharmacology.

The conversion of active to latent plasminogen activator inhibitor-1 is an energetically silent event.

A. Gils, C. Boudier, P. Declerck, 2005, Biophysical journal.

Biopharmaceuticals: Reference Products and Biosimilars to Treat Inflammatory Diseases.

A. Gils, P. Declerck, A. Bertolotto, 2017, Therapeutic drug monitoring.

Characterization and Comparative Evaluation of a Novel PAI-1 Inhibitor

A. Gils, H. Nar, P. Declerck, 2002, Thrombosis and Haemostasis.

The Roles of Selected Arginine and Lysine Residues of TAFI (Pro-CPU) in Its Activation to TAFIa by the Thrombin-Thrombomodulin Complex*

A. Gils, M. Whitlow, P. Declerck, 2009, Journal of Biological Chemistry.

Lys 42/43/44 and Arg 12 of thrombin-activable fibrinolysis inhibitor comprise a thrombomodulin exosite essential for its antifibrinolytic potential

A. Gils, P. Declerck, J. Weitz, 2017, Thrombosis and Haemostasis.

Heterobifunctional PEG Ligands for Bioconjugation Reactions on Iron Oxide Nanoparticles

T. Verbiest, J. Lammertyn, G. Koeckelberghs, 2014, PloS one.

Selective protein purification by PEG–IDA-functionalized iron oxide nanoparticles

K. Clays, T. Verbiest, A. Gils, 2015 .

A Genome-wide Study of Common and Rare Genetic Variants Associated with Circulating Thrombin Activatable Fibrinolysis Inhibitor

O. Melander, G. Engström, A. Gils, 2018, Thrombosis and Haemostasis.

Vasculin, a novel vascular protein differentially expressed in human atherogenesis.

Sylvia Heeneman, Ann Gils, M. Daemen, 2003, Blood.

Function-stabilizing mechanism of plasminogen activator inhibitor type 1 induced upon binding to alpha1-acid glycoprotein.

A. Gils, P. Declerck, C. Cierniewski, 2005, Biochemistry.

Crohn's Disease: Infliximab Trough Levels and CRP During Infliximab-Immunomodulator Combination Treatment Are Associated With Clinical Outcome After Immunomodulator Withdrawal

P. Rutgeerts, S. Vermeire, I. Cleynen, 2011 .

Molecular cloning, expression and mutational analysis of wheat xylanase inhibitor TAXI-I

G. Volckaert, J. Robben, J. Delcour, 2006 .

Early serial trough and antidrug antibody level measurements predict clinical outcome of infliximab and adalimumab treatment

G Van Assche, P. Rutgeerts, S. Vermeire, 2011, Gut.

539 Anti-TNF-Induced Skin Manifestations in IBD Patients: Role for Increased Drug Exposure?

P. Rutgeerts, S. Vermeire, I. Cleynen, 2015 .

Transferability of antibody pairs from ELISA to fiber optic surface plasmon resonance for infliximab detection

Jeroen Lammertyn, Thierry Verbiest, Maarten Bloemen, 2015, Photonics West - Biomedical Optics.

Determination of coagulation and fibrinolysis markers upon anti-TAFI treatment in a mouse thromboembolism model

A. Gils, P. Declerck, M. Hoylaerts, 2011 .

Ara h 1 protein-antibody dissociation study: evidence for binding inhomogeneities on a molecular scale.

J. Lammertyn, D. Spasic, A. Gils, 2015, New biotechnology.

University of Groningen Personalized, Web-Based, Guided Self-Help for Patients With Medically Unexplained Symptoms in Primary Care

A. Gils, D. Hanssen, H. Burger, 2019 .

Protocol Personalized , Web-Based , Guided Self-Help for Patients With Medically Unexplained Symptoms in Primary Care : Protocol for a Randomized Controlled Trial

A. Gils, D. Hanssen, H. Burger, 2019 .

Development of ELISAs Measuring the Extent of TAFI Activation

A. Gils, C. Jern, P. Declerck, 2005, Arteriosclerosis, thrombosis, and vascular biology.

Defining a minimal effective serum trough concentration of secukinumab in psoriasis: a step towards personalized therapy.

J. Lambert, A. Gils, E. Brouwers, 2019, The Journal of investigative dermatology.

P589 A population pharmacokinetic model to improve mucosal healing upon golimumab induction therapy in patients with ulcerative colitis

S. Vermeire, A. Gils, M. Ferrante, 2019, Journal of Crohn's and Colitis.

P649 Comparison of the KU Leuven ustekinumab concentration assay and the antibodies-to-ustekinumab assay with assays developed at Janssen R&D and used in clinical studies of IBD patients

G. Shankar, A. Gils, J. Marini, 2018 .

Increased zymogen activity of thrombin‐activatable fibrinolysis inhibitor prolongs clot lysis

A. Gils, G. Compernolle, N. Mishra, 2012, Journal of thrombosis and haemostasis : JTH.

Identification and characterisation of monoclonal antibodies that impair the activation of human thrombin activatable fibrinolysis inhibitor through different mechanisms

A. Gils, P. Declerck, E. Vercauteren, 2011, Thrombosis and Haemostasis.

Biochemical Importance of Glycosylation in Thrombin Activatable Fibrinolysis Inhibitor

A. Gils, P. Declerck, G. Compernolle, 2008, Circulation research.

P464 Vedolizumab concentrations in colonic mucosal tissue of ulcerative colitis patients inversely correlate with the severity of inflammation

S. Vermeire, A. Gils, M. Ferrante, 2020, Journal of Crohn's and Colitis.

P601 Development and validation of dried blood spot sampling as a tool to identify the best time point to measure predictive ustekinumab serum concentrations in patients with Crohn’s disease

S. Vermeire, A. Gils, M. Ferrante, 2020 .

P342 A population pharmacokinetic model to support therapeutic drug monitoring during vedolizumab therapy

S. Vermeire, A. Gils, M. Ferrante, 2019, Journal of Crohn's and Colitis.

DOP029 Clinical relevance of detecting anti-infliximab antibodies with a drug-tolerant assay: post-hoc analysis of the taxit trial.

S. Vermeire, T. Van Stappen, A. Gils, 2017, Journal of Crohn's & colitis.

Pharmacokinetic Modeling and Simulation of Biologicals in Inflammatory Bowel Disease: The Dawning of a New Era for Personalized Treatment.

S. Vermeire, A. Gils, E. Dreesen, 2016, Current drug targets.

Blocking α4β7 Integrin Through Vedolizumab: Necessary but not Sufficient?

A. Gils, E. Dreesen, 2017, Journal of Crohn's & colitis.

Identification of a novel, nanobody‐induced, mechanism of TAFI inactivation and its in vivo application

S. Muyldermans, A. Gils, P. Declerck, 2014, Journal of Thrombosis and Haemostasis.

Monoclonal antibodies targeting the antifibrinolytic activity of activated thrombin‐activatable fibrinolysis inhibitor but not the anti‐inflammatory activity on osteopontin and C5a

A. Gils, P. Declerck, C. T. Ammollo, 2013, Journal of thrombosis and haemostasis : JTH.

Plasmin and the thrombin–thrombomodulin complex both contribute to thrombin‐activatable fibrinolysis inhibitor activation in whole blood model thrombi

A. Gils, N. Mutch, P. Declerck, 2013, Journal of thrombosis and haemostasis : JTH.

Haemostatic biomarkers are associated with long-term recurrent vascular events after ischaemic stroke

A. Gils, C. Jern, P. Redfors, 2016, Thrombosis and Haemostasis.

Subtle structural differences between human and mouse PAI-1 reveal the basis for biochemical differences.

A. Gils, P. Declerck, S. Strelkov, 2010, Journal of structural biology.

1159 Results on the Optimisation Phase of the Prospective Controlled Trough Level Adapted Infliximab Treatment (TAXIT) Trial

P. Rutgeerts, S. Vermeire, A. Gils, 2012 .

A. Gils, P. Declerck, E. Dreesen, 2015 .

P603 Vedolizumab trough levels at Week 6 predict endoscopic and clinical remission in inflammatory bowel disease

A. Gils, G. Novak, J. Hanžel, 2018 .

Letter: detection of infliximab levels and anti‐infliximab antibodies – comparison of three different assays; authors’ reply

S. Vermeire, A. Gils, J. Kleibeuker, 2013, Alimentary Pharmacology and Therapeutics.